3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Dermatologic
1
Conditions
Skin Neoplasms
1
Melanoma
1
Interventions
Nivolumab
18
Ipilimumab
16
pembrolizumab
15
Cyclophosphamide
13
trametinib
9
Radiotherapy
8
dabrafenib
6
Interleukin-2
6
sargramostim
5
fludarabine phosphate
5
aldesleukin
5
Vemurafenib
5
Peripheral Blood Stem Cell Transplantation
5
Fluorouracil
5
130-nm albumin-bound paclitaxel
5
fludarabine
4
Radiosurgery
4
Melphalan
4
Celecoxib
4
encorafenib
3
durvalumab
3
binimetinib
3
avelumab
3
Vorinostat
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Leucovorin
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Cytarabine
3
Capecitabine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
reolysin
×
Dermatologic
×
Clear all
NCT03282188
2018-05-04
REO13 Melanoma With of Without GM-CSF
University of Leeds
Phase 1/2
Withdrawn